Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 4/20 | 0.42 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.38 |
| ▸ | FEN1 | P39748 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 12/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24252351 | 0.92 | SCN9A (0.41) | SCN9AALOX5APFEN1PDE10AAAK1 | |
| Formic Acid SCHEMBL30467675 | 0.88 | SCN9A (0.38) | SCN9AALOX5APFEN1PDE10AAAK1 | |
| Formic Acid SCHEMBL25266455 | 0.88 | SCN9A (0.38) | SCN9AALOX5APFEN1PDE10AAAK1 | |
| SCHEMBL25212150 | 0.86 | SCN9A (0.37) | SCN9AALOX5APFEN1PDE10AAAK1 | |
| SCHEMBL26771381 | 0.86 | PDE10A (0.35) | PDE10AAAK1 | |
| SCHEMBL26771236 | 0.85 | PDE10A (0.34) | SCN9APDE10A | |
| SCHEMBL26771021 | 0.84 | PDE10A (0.45) | PDE10A | |
| SCHEMBL26771277 | 0.84 | PDE10A (0.34) | PDE10AAAK1 | |
| SCHEMBL26771314 | 0.84 | PDE10A (0.36) | PDE10A | |
| SCHEMBL26771272 | 0.83 | PDE10A (0.37) | PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | CFB, CFH, C9 | SCN9A 3732/4885ALOX5AP 246/4885FEN1 2638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.